Rhythm Biosciences (ASX:RHY) secured an agreement with UK-incorporated cancer diagnostics company Digistain for the supply of its geneType genetic test portfolio, according to a Wednesday filing with the Australian bourse.
The deal grants Digistain the right to market and distribute the genetic test portfolio in Southeast Asia for an initial 12-month term, with renewal provisions supporting scalable expansion, the filing said.
Revenue is generated per test as samples are processed and reported, with invoicing done monthly and 30-day payment terms, per the filing.